Aires Pharma signs option deal with Novartis based on Aironite worth up to $250 million; raises $20 million


Privately-held, US clinical stage pharmaceutical company Aires Pharmaceuticals had a successful fundraising…

Aires PharmaceuticalsAironiteFinancialLicensingMergers & AcquisitionsNovartisPharmaceuticalRespiratory and Pulmonary

Sandoz/Novartis buy Oriel Therapeutics, gaining rights to portfolio of products targeting asthma and COPD


Swiss drug major Novartis’ generics subsidiary Sandoz has signed a definitive agreement to acquire…

GenericsMergers & AcquisitionsNovartisPharmaceuticalRespiratory and PulmonarySandoz

Back to top